(Q46796622)

25 December 2017

title

Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil (English)

1 reference

25 December 2017

author name string

T Y Langaee

1

1 reference

25 December 2017

Y Gong

2

1 reference

25 December 2017

H N Yarandi

3

1 reference

25 December 2017

D A Katz

4

1 reference

25 December 2017

R M Cooper-DeHoff

5

1 reference

25 December 2017

C J Pepine

6

1 reference

25 December 2017

J A Johnson

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

25 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

25 December 2017

volume

81

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

386-391

1 reference

25 December 2017

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

Renal and hepatic family 3A cytochromes P450 (CYP3a) in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

Genetic variation analyses by Pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

A New Statistical Method for Haplotype Reconstruction from Population Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

The genetic determinants of the CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

Growth factors downregulate vascular smooth muscle thromboxane receptors independent of cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

CYP3A5 genotype is associated with elevated blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100090

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100090

1 reference

25 December 2017

1 reference

25 December 2017